MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.


MindMed (Mind Medicine Inc.) has various drugs in clinical trials. LSD for anxiety is the most advanced (Phase 2b), with LSD for suicide headaches and LSD microdosing for adult ADHD following shortly behind that (Project Lucy). MindMed is also researching 18-MC for opioid withdrawal & addiction and is in the early stages of research with MDMA and DMT. In August 2020, they also registered a trial with MDMA and LSD.

18-MC (synthetic molecule derived from ibogaine) was bought from Savant HWP Inc. and is currently in Phase I of clinical trials and is well-tolerated so far.

Part of the work they do is in collaboration with Liechti Lab and NYU, to which they granted $5 million for the launch of their Center for Psychedelic Medicine.

In November 2020, the company also launched their ‘Albert’ initiative, announcing (more) plans for making digital apps/platforms around psychedelic therapies.

“MindMed gains exclusive worldwide rights to data, compounds, and patent rights associated with the Liechti laboratory’s research with LSD and other psychedelic compounds, including data from preclinical studies and eight completed or ongoing LSD clinical trials.”

MindMed is listed on the stock exchange and is also known for having Kevin O’Leary (Shark Tank) and Bruce Linton (Canopy Growth) as investors. To date, the total investment in MindMed is $30.2 million (updated: now over $50 million). The company has now been listed on the Nasdaq under the ticker MNMD.

MindMed has raised $175.8M in funding over 8 rounds. Their latest funding was raised on Mar 8, 2021, from a Post-IPO Equity round.

Matthew Johnson, Peter Gasser and Kim Kuypers are three prominent advisors to the company.


Company Information

MindMed Website

October, 2019


B2B B2C Pharmaceutical Biotech

Compounds of Interest
LSD Ibogaine MDMA

Topics of Interest
Anxiety Pain Addiction

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects (Cision, 03 March 2022)

Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety (Novamind, 16 March 2022)

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They? (Psychedelic Spotlight, 21 April 2022)

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures (Yahoo, 16 November 2021)
Mind Medicine (MindMed) announced that it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the "LSD Study").

MindMed Lists on NEO to Become World’s First Psychedelic Pharmaceutical Company to Go Public (Business Wire, 03 March 2020)
MindMed is the first psychedelic company to go public. It has listed on the NEO (Canada) exchange in March 2020.

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin (, 30 November 2021)

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System (, 09 December 2021)

MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder (, 21 December 2021)


HQ / Office New York, NY, USA